Terms: = Lymphoma AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Treatment
59 results:
1. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2
Ichikawa T; Suekane A; Nakahata S; Iha H; Shimoda K; Murakami T; Morishita K
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474089
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical characteristics and prognosis of 28 cases of infant acute lymphoblastic leukemia].
Shi Y; Lu Y; Zhang RD; Zhang YY; Lin W; Yu JJ; Wu Y; Fan J; Qi PJ; Huang PL; Cai LX; Huang Q; Zhang P; Sun YM; Liu Y; Zheng HY
Zhonghua Er Ke Za Zhi; 2024 Jan; 62(1):49-54. PubMed ID: 38154977
[No Abstract] [Full Text] [Related]
3. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
[TBL] [Abstract] [Full Text] [Related]
4. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
[TBL] [Abstract] [Full Text] [Related]
5. Frequency and Prognostic Impact of
Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
[TBL] [Abstract] [Full Text] [Related]
6. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract] [Full Text] [Related]
7. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by mycn/DKK3 in B-ALL.
Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
[TBL] [Abstract] [Full Text] [Related]
8. ALK ligand ALKAL2 potentiates mycn-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract] [Full Text] [Related]
9. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and mycn depletion.
Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
[TBL] [Abstract] [Full Text] [Related]
10. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
[TBL] [Abstract] [Full Text] [Related]
11. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract] [Full Text] [Related]
12. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/mycn-coamplified Neuroblastoma.
Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
[TBL] [Abstract] [Full Text] [Related]
13. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of mycn status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract] [Full Text] [Related]
14. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
[TBL] [Abstract] [Full Text] [Related]
15. Autophagy Promotes Survival of CHP-212 Neuroblastoma Cells Treated With Casiopeínas®.
Vázquez-Aguirre A; Gutiérrez AG; Esparza RM; Hernández-Lemus E; Ruiz-Azuara L; Mejía C
Anticancer Res; 2019 Jul; 39(7):3687-3695. PubMed ID: 31262895
[TBL] [Abstract] [Full Text] [Related]
16. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
[TBL] [Abstract] [Full Text] [Related]
17. ALK positively regulates mycn activity through repression of HBP1 expression.
Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
[TBL] [Abstract] [Full Text] [Related]
18. Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia.
Tang C; Li MH; Chen YL; Sun HY; Liu SL; Zheng WW; Zhang MY; Li H; Fu W; Zhang WJ; Liang AB; Tang ZH; Hong DL; Zhou BS; Duan CW
J Exp Clin Cancer Res; 2018 Aug; 37(1):204. PubMed ID: 30157922
[TBL] [Abstract] [Full Text] [Related]
19. mycn is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
[TBL] [Abstract] [Full Text] [Related]
20. IRE1α RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers.
Xie H; Tang CH; Song JH; Mancuso A; Del Valle JR; Cao J; Xiang Y; Dang CV; Lan R; Sanchez DJ; Keith B; Hu CC; Simon MC
J Clin Invest; 2018 Apr; 128(4):1300-1316. PubMed ID: 29381485
[TBL] [Abstract] [Full Text] [Related]
[Next]
